All Stories

  1. Circulating microRNA changes in patients with impaired glucose regulation
  2. Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson’s disease
  3. Neuromyelitis optica spectrum disorder in three generations of a Chinese family
  4. Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats
  5. GRIN2B promoter methylation deficits in early-onset schizophrenia and its association with cognitive function
  6. Lower uric acid is associated with poor short-term outcome and a higher frequency of posterior arterial involvement in ischemic stroke
  7. Increased DNA methylation in the parvalbumin gene promoter is associated with methamphetamine dependence
  8. Association of polymorphisms in GAD1 and GAD2 genes with methamphetamine dependence
  9. DAT1 methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD
  10. Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine
  11. Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain
  12. Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment
  13. TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs
  14. Effect of Methamphetamine Exposure on Expression of Calcium Binding Proteins in Rat Frontal Cortex and Hippocampus
  15. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
  16. Does DNA methylation influence the effects of psychiatric drugs?
  17. Does elevated peripheral benzodiazepine receptor gene expression relate to cognitive deficits in methamphetamine dependence?
  18. Concurrent Risperidone Administration Attenuates the Development of Locomotor Sensitization Following Sub-Chronic Phencyclidine in Rats
  19. Association of brain-derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder
  20. BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence
  21. Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism
  22. Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action
  23. Analysis of sociability and preference for social novelty in the acute and subchronic phencyclidine rat
  24. Numerical Methods on Population Balances
  25. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms
  26. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics
  27. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia
  28. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
  29. SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects
  30. Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia
  31. Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population
  32. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
  33. Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population
  34. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response
  35. The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients
  36. Histamine and antipsychotic drug-induced weight gain
  37. Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration
  38. Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
  39. An association between genotypic variations and protein expression of the glial glutamate transporter 2 in the human nucleus accumbens
  40. The Effect of Chronic Antipsychotic Drug on Hypothalamic Expression of Neural Nitric Oxide Synthase and Dopamine D2 Receptor in the Male Rat
  41. Special issue on Pharmacogenetics
  42. The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
  43. The Pharmacogenetics of Antipsychotic Treatment
  44. Learning and Memory Alterations Are Associated with Hippocampal N-acetylaspartate in a Rat Model of Depression as Measured by 1H-MRS
  45. Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine
  46. The Dose‐Dependent Effect of Chronic Administration of Haloperidol, Risperidone, and Quetiapine on Sexual Behavior in the Male Rat
  47. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response
  48. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes
  49. Functional consequences of twoHTR2Cpolymorphisms associated with antipsychotic-induced weight gain
  50. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
  51. Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: A magnetic resonance study
  52. Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder
  53. Adolescent escitalopram administration modifies neurochemical alterations in the hippocampus of maternally separated rats
  54. The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks
  55. Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse
  56. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism
  57. The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues
  58. Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone
  59. Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat
  60. Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat
  61. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
  62. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 ‘knockout’ mice
  63. Functional Pharmacogenetics of Serotonin Receptors in Psychiatric Drug Action
  64. Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat
  65. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors
  66. Single drop behaviour in a high shear granulator
  67. Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat
  68. The neurochemistry of schizophrenia
  69. Effect of acute tryptophan depletion on noradrenaline and dopamine in the rat brain
  70. PHARMACOGENETICS OF THE METABOLIC CONSEQUENCES OF ANTIPSYCHOTIC DRUGS
  71. PHARMACOGENETICS OF NEGATIVE SYMPTOM RESPONSE TO ANTIPSYCHOTIC DRUGS - THE ROLE OF 5-HT SYSTEMS
  72. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia
  73. Erratum
  74. Acute tryptophan depletion does not alter central or plasma brain-derived neurotrophic factor in the rat
  75. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats
  76. The impact of pharmacogenetics on the development and use of antipsychotic drugs
  77. Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus
  78. 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity
  79. The neuronal pathology of schizophrenia: molecules and mechanisms: Table 1
  80. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat
  81. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats
  82. Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT2A receptor binding in the rat
  83. Subcellular Pathology of Human Neurodegenerative Disorders: Alzheimer-Type Dementia and Huntington's Disease
  84. Effect of 5-HT1A Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients
  85. The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat
  86. Schizophrenia, antipsychotics and metabolic disease
  87. Pharmacogenetics of schizophrenia
  88. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics
  89. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm
  90. Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus
  91. Selective increases in the cytokine, TNF , in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs
  92. Metabolic syndrome and schizophrenia * Author's reply:
  93. Actions of antipsychotic drugs on pancreatic  -cell function: contrasting effects of clozapine and haloperidol
  94. An in vitro model of inflammatory neurodegeneration and its neuroprotection
  95. The neurochemistry of schizophrenia
  96. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment
  97. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol
  98. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis
  99. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain
  100. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response
  101. Chronic haloperidol or clozapine treatment does not alter parvalbumin immunoreactivity in the rat frontal cortex or hippocampus
  102. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders
  103. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat
  104. Receptor Mechanisms in the treatment of Schizophrenia
  105. Reduced n-acetylaspartate in the temporal cortex of rats reared in isolation
  106. Calcium binding protein markers of GABA deficits in schizophrenia — post mortem studies and animal models
  107. Region specific changes in forebrain 5-hydroxytryptamine1a and 5-hydroxytryptamine2a receptors in isolation-reared rats: an in vitro autoradiography study
  108. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia
  109. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia
  110. Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats
  111. N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study
  112. Polymorphism of the Promoter Region of the Serotonin 5-HT 2C Receptor Gene and Clozapine-Induced Weight Gain
  113. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat
  114. Increased Concentrations of the Neurotoxin 3-Hydroxykynurenine in the Frontal Cortex of HIV-1-Positive Patients
  115. Are Striatal Dopamine D4 Receptors Increased in Schizophrenia?
  116. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins
  117. Weight gain, antipsychotic drug treatment and pharmacogenomics
  118. Neuronal calcium-binding proteins and schizophrenia
  119. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism
  120. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia
  121. Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
  122. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia
  123. Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons
  124. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease
  125. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study
  126. Brain Neurotransmitter Deficits in Mice Transgenic for the Huntington’s Disease Mutation
  127. Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells
  128. GABAergic neuronal subtypes in the human frontal cortex — development and deficits in schizophrenia
  129. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity
  130. Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia
  131. Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective
  132. Plasma homovanillic acid in untreated schizophrenia — relationship with symptomatology and sex
  133. Agonist-stimulated GTPγ[35S] binding to 5-HT1A receptors in human post-mortem brain
  134. Dopamine receptors, antipsychotic action and schizophrenia
  135. Antipsychotic drug affinities at α2-adrenoceptor subtypes in post-mortem human brain
  136. Developments in antipsychotic drugs – an update
  137. Receptor mechanisms of antipsychotic drug atypicality
  138. Receptor mechanisms of antipsychotic drug atypicality
  139. Increased density of glutamate/N-methyl-d-aspartate receptors in putamen from schizophrenic patients
  140. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease
  141. S.17.03 Antipsychotic drugs and neurotransmitter receptor regulation
  142. Deficits of [3H]d-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia
  143. What is an atypical antipsychotic?
  144. Schizophrenia - advances in drug therapy
  145. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
  146. 5-HT receptors, genes and antipsychotic mechanisms
  147. An improved model for examining delayed excitotoxic neurodegeneration in isolated chick retina
  148. Neurotransmitter receptors, genes and schizophrenia
  149. Imidazoline binding sites in Huntington's and Parkinson's disease putamen
  150. The Importance of Dopamine D4 Receptors in the Action and Development of Antipsychotic Agents
  151. Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders
  152. Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research
  153. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia
  154. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients
  155. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases
  156. An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease
  157. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia
  158. New Approaches to the Drug Treatment of Schizophrenia
  159. Neurotransmitter Systems in Schizophrenia
  160. Neocortical neurotransmitter markers in Huntington's disease
  161. Arachidonic Acid: A Common Link in the Biology of Schizophrenia?
  162. Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease
  163. Glutamate in Huntington's disease
  164. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia
  165. Differential regulation of cardiac α- and β-adrenoceptors by the sympathetic nervous system
  166. Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro
  167. D-aspartate binding to the glutamate uptake site in human brain tissue ? effects of leucotomy
  168. Hippocampal benzodiazepine receptors in schizophrenia
  169. Hippocampal tin, aluminum and zinc in Alzheimer's disease
  170. Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study
  171. Neurochemical abnormalities in huntington's disease: Neurotoxic mechanisms and neurotransmitter changes
  172. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue
  173. Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study
  174. Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality
  175. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease
  176. An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures
  177. Developments in the drug treatment of schizophrenia
  178. Erratum
  179. Erratum
  180. Studies on brain monoamine oxidase: a laboratory investigation in neurochemistry for first-year undergraduates
  181. The ratio of plasma phenylalanine to other large neutral amino acids is not a risk factor for tardive dyskinesia
  182. Neuroanatomical Correlates of Skin Conductance Orienting in Normal Humans: A Magnetic Resonance Imaging Study
  183. Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable O-phthalaldehyde-sulphite derivatives
  184. Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection
  185. [3H]Ditolylguanidine binding to human brain σ sites is diminished after haloperidol treatment
  186. No deficit of pallidal D2 dopamine receptors in Huntington's disease
  187. Structural and Functional Characteristics of the Corpus Callosum in Schizophrenics, Psychiatric Controls, and Normal Controls
  188. Pallidal GABA and chorea in Huntington's disease
  189. [3H]Nipecotic Acid Binding to ?-Aminobutyric Acid Uptake Sites in Postmortem Human Brain
  190. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia
  191. Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex
  192. Serotonin concentrations and turnover in brains of depressed suicides
  193. Tissue banking and EURAGE
  194. INCREASED BRAIN 3-HYDROXYKYNURENINE IN HUNTINGTON'S DISEASE
  195. (3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
  196. [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia
  197. Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia
  198. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata
  199. Neuropeptides in Alzheimer's disease: a postmortem study
  200. Reduced d-[3H]aspartate binding in Down's syndrome brains
  201. Alzheimer-like cortical amino-acid changes in elderly Down's syndrome
  202. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms
  203. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains
  204. ALUMINIUM AND ALZHEIMER'S DISEASE
  205. Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue
  206. Post-mortem neurochemistry of schizophrenia
  207. GLUTAMATE DEHYDROGENASE ACTIVITY IN AMYOTROPHIC LATERAL SCLEROSIS
  208. Pathologic Heterogeneity of Alzheimer's Disease-Reply
  209. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
  210. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease
  211. Brain Quinolinic Acid in Huntington's Disease
  212. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea
  213. ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA
  214. A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease
  215. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain
  216. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.
  217. Age and Histopathologic Heterogeneity in Alzheimer's Disease
  218. DOPAMINE RECEPTOR ASYMMETRY IN SCHIZOPHRENIA
  219. HPLC analysis of somatostatin related peptides in putamen of Huntington's Disease patients
  220. Maintenance of cortical somatostatin and monoamine levels in the rat does not require intact cholinergic innervation
  221. Decreased brown adipose tissue thermogenic activity following a reduction in brain serotonin by intraventricular p-chlorophenylalanine
  222. A disorder of cortical GABAergic innervation in Alzheimer's disease
  223. Human brain dopamine receptors in children and aging adults
  224. Neuropathology of Huntington's disease
  225. Region-specific loss of glutamate innervation in Alzheimer's disease
  226. LITHIUM PROPHYLAXIS INHIBITS CHOLINE TRANSPORT IN POST-MORTEM BRAIN
  227. Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease
  228. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease
  229. Regional distribution of a novel peptide (P7 of 1B236) immunoreactivity in the human central nervous system
  230. Striatal dopamine and homovanillic acid in Huntington's Disease
  231. Cytological brush entrapment: a hazard in the stomach postoperatively.
  232. Dopamine D2 receptor density remains constant in treated Parkinson's disease
  233. Brain serotonin receptors in Huntington's disease
  234. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations
  235. Corticotropin-Releasing Factor-like Immunoreactivity in Senile Dementia of the Alzheimer Type
  236. ALZHEIMER-LIKE BRAIN MONOAMINE DEFICITS IN ADULTS WITH DOWN'S SYNDROME
  237. Recombinant DNA studies on stored necropsy brain samples from patients with Huntington's chorea.
  238. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease
  239. Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset
  240. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases
  241. Identification of gram-negative bacilli using the autobac IDX
  242. Decreased Proline Endopeptidase Activity in the Basal Ganglia in Huntington's Disease
  243. TETRAHYDROBIOPTERIN METABOLISM IN DEPRESSION
  244. Noradrenaline and schizophrenia
  245. Reduced binding of [3H]ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type
  246. The pharmacology of Parkinson's disease: l-dopa and beyond
  247. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia
  248. Neuropharmacology: Pathophysiology of schizophrenia — causal role for dopamine or noradrenaline?
  249. SEROTONIN RECEPTORS IN SUICIDE VICTIMS
  250. Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type
  251. Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors
  252. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients
  253. Neurotensin in the adrenal medulla
  254. Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls
  255. Parkinson's disease putamen: Normal concentration of synaptic membrane marker antigens
  256. THIORIDAZINE IS NOT SPECIFIC FOR LIMBIC DOPAMINE RECEPTORS
  257. Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic technique
  258. DOPAMINE RECEPTORS IN POST-MORTEM SCHIZOPHRENIC BRAINS
  259. The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain
  260. DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS
  261. The Determination and Distribution of2-Phenylethylamine in Sheep Brain
  262. Deficient production of tyramine and octopamine in cases of depression
  263. Phenylethylamine — a role in mental illness?
  264. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration
  265. The effect of urinary pH and flow rate on monoamine output
  266. The urinary excretion of 2-phenylethylamine in phenylketonuria
  267. Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?
  268. Gas chromatographic detection of N-methyl-2-phenylethylamine: a new component of human urine
  269. A method for the estimation of 2-phenylethylamine in human urine by gas chromatography
  270. Neurochemical Studies in Human Postmortem Brain Tissue
  271. Neurochemistry of Human Postmortem Brain